| Primary |
| Product Used For Unknown Indication |
19.4% |
| Haemolytic Uraemic Syndrome |
16.0% |
| Hypertension |
15.2% |
| Prophylaxis |
12.3% |
| Paroxysmal Nocturnal Haemoglobinuria |
6.3% |
| Renal Transplant |
3.7% |
| Routine Health Maintenance |
3.7% |
| Depression |
2.6% |
| Immunosuppression |
2.6% |
| Anticoagulant Therapy |
2.4% |
| Nausea |
2.4% |
| Gastrooesophageal Reflux Disease |
2.1% |
| Supplementation Therapy |
1.8% |
| Anaemia |
1.6% |
| Anxiety |
1.6% |
| Pain |
1.6% |
| Antibiotic Therapy |
1.3% |
| Infection Prophylaxis |
1.3% |
| Pyrexia |
1.3% |
| Constipation |
1.0% |
|
| Gastroenteritis |
11.7% |
| Renal Impairment |
11.7% |
| Pyrexia |
10.0% |
| Urinary Tract Infection |
10.0% |
| Sepsis |
8.3% |
| Infection |
6.7% |
| Nausea |
5.0% |
| Pneumonia |
5.0% |
| Pyelonephritis |
5.0% |
| Viral Infection |
5.0% |
| Petechiae |
3.3% |
| Platelet Count Decreased |
3.3% |
| Pulmonary Embolism |
3.3% |
| Abdominal Pain |
1.7% |
| Abdominal Pain Upper |
1.7% |
| Abdominal Sepsis |
1.7% |
| Abortion Induced |
1.7% |
| Anaemia |
1.7% |
| Cardiac Failure |
1.7% |
| Death |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
39.3% |
| Paroxysmal Nocturnal Haemoglobinuria |
10.9% |
| Hypertension |
10.4% |
| Anticoagulant Therapy |
10.1% |
| Haemolytic Uraemic Syndrome |
6.8% |
| Prophylaxis |
5.0% |
| Convulsion |
3.5% |
| Immunosuppression |
2.0% |
| Infection Prophylaxis |
1.5% |
| Aplasia Pure Red Cell |
1.3% |
| Autoimmune Haemolytic Anaemia |
1.3% |
| Reflux Oesophagitis |
1.3% |
| Transplant Rejection |
1.3% |
| Renal Transplant |
1.0% |
| Pyrexia |
0.9% |
| Anaemia |
0.8% |
| Antibiotic Therapy |
0.8% |
| Gastrooesophageal Reflux Disease |
0.8% |
| Prophylaxis Against Transplant Rejection |
0.8% |
| Thrombosis Prophylaxis |
0.8% |
|
| Pyelonephritis |
28.8% |
| Urinary Tract Infection |
23.2% |
| Infection |
5.6% |
| Multi-organ Failure |
5.6% |
| Pyrexia |
4.8% |
| Pancreatitis |
4.0% |
| Abdominal Sepsis |
3.2% |
| Drug Ineffective |
3.2% |
| Gastroenteritis |
2.4% |
| Laboratory Test Abnormal |
2.4% |
| Meningitis |
2.4% |
| Abdominal Pain |
1.6% |
| Anaemia |
1.6% |
| Gastrointestinal Haemorrhage |
1.6% |
| Haemolysis |
1.6% |
| Kidney Transplant Rejection |
1.6% |
| Meningococcal Sepsis |
1.6% |
| Post Procedural Haemorrhage |
1.6% |
| Renal Impairment |
1.6% |
| Ruptured Cerebral Aneurysm |
1.6% |
|
| Concomitant |
| Aplastic Anaemia |
26.5% |
| Product Used For Unknown Indication |
20.6% |
| Bone Marrow Conditioning Regimen |
14.7% |
| Renal Transplant |
8.8% |
| Paroxysmal Nocturnal Haemoglobinuria |
7.4% |
| Myelodysplastic Syndrome |
5.9% |
| Thrombosis Prophylaxis |
2.9% |
| Antiphospholipid Syndrome |
1.5% |
| Aspergillus Infection |
1.5% |
| Hypertension |
1.5% |
| Portal Vein Thrombosis |
1.5% |
| Prophylaxis |
1.5% |
| Prophylaxis Against Transplant Rejection |
1.5% |
| Pyelonephritis |
1.5% |
| Stem Cell Transplant |
1.5% |
| Systemic Lupus Erythematosus |
1.5% |
|
| Paroxysmal Nocturnal Haemoglobinuria |
18.2% |
| Haemolytic Uraemic Syndrome |
9.1% |
| Spinal Deformity |
9.1% |
| Transplant Failure |
9.1% |
| Budd-chiari Syndrome |
4.5% |
| Diabetes Mellitus |
4.5% |
| Dialysis |
4.5% |
| Dyspnoea |
4.5% |
| Fungal Infection |
4.5% |
| Haemolysis |
4.5% |
| Hepatocellular Injury |
4.5% |
| Normal Newborn |
4.5% |
| Plasma Cell Myeloma |
4.5% |
| Somnolence |
4.5% |
| Vomiting |
4.5% |
| Weight Increased |
4.5% |
|
